Immunomic Therapeutics’ CEO to Participate in Panel at MD Life Sciences’ Bio Innovation Conference Meeting 2020
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio Innovation virtual conference in Maryland. On Monday, October 5, Chief Executive Officer at Immunomic, Dr. Bill Hearl, will participate in a panel titled, “Pandemic & Risk Mitigation: A Focus on Preparation & Resiliency” alongside Novavax’s President and CEO, Stanley Erck, and Emmes’ President, Anne Lindblad.
The Bio Innovation Conference is presented by Maryland Life Sciences, a division of the Maryland Tech Council that is driving the future of life sciences in Maryland. This conference provides a forum for professionals from industry, academia and government to discuss trends and insight into Maryland’s burgeoning life sciences industry and topics related to funding, structuring, commercialization and government relations.
Panel details are as follows:
Title: Pandemic & Risk Mitigation: A Focus on Preparation & Resiliency
Panel Category: Life Science Track
Linda Segal, Principal, The McCormick Group
Gayatri Varma, Director, Transactions, Business Development & Licensing, AstraZeneca
Stanley Erck, President and CEO, Novavax
Bill Hearl, Ph.D., CEO, Immunomic Therapeutics
Anne Lindblad, Ph.D., President, Emmes
Panel Date and Time: Monday, October 5, 2020 10:25 AM
Location: MD Life Science Bio Innovation Virtual Event
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI’s UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
Source: Immunomic Therapeutics, Inc.